New Batch Of Psilocybin Microdose Capsules Is Ready, Learn All The Details
New Batch Of Psilocybin Microdose Capsules Is Ready, Learn All The Details
NOVA's work focuses on developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders and debilitating chronic conditions. Canadian-based psychedelics company Nova Mentis Life Science Corp. (OTCQB:NMLSF), or NOVA, is collaborating with the Toronto Institute of Pharmaceutical Technology (TIPT), a Health Canada-licensed GMP manufacturing and testing facility, to complete the production of an engineering quantity of psilocybin microdose capsules.
加拿大迷幻藥公司Nova Mentis生命科學公司(OTCQB：NMLSF)，或Nova，正在與多倫多製藥技術研究所(TIP)，加拿大衞生部許可的GMP製造和測試設施，以完成工程量裸蓋菇素微劑量膠囊的生產。
The partners are moving forward with the release testing stage in order to generate data required by Canada's application process towards advancing a Phase IIa clinical trial on psilocybin microdose therapy for Fragile X Syndrome (FXS), the leading genetic cause of Autism Spectrum Disorder (ASD).
合作伙伴正在推進版本測試階段，以便生成加拿大應用程序所需的數據，以實現推進裸蓋菇素微劑量治療脆性X綜合徵的IIa期臨牀試驗，自閉症譜系障礙(ASD)的主要遺傳原因。
The company has partnered with contract research organization KGK Science Inc. to develop its psilocybin drug portfolio by jointly submitting the Health Canada clinical trial application.
該公司已經與合同研究機構KGK科學公司合作，通過聯合提交加拿大衞生部的臨牀試驗申請來開發其裸蓋菇素藥物組合。
NOVA's work focuses on developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders and debilitating chronic conditions.
Nova的工作重點是開發診斷和基於裸蓋菇素的療法，用於治療神經炎性疾病和使人虛弱的慢性疾病。
The company achieved orphan drug designation in both the US and the European Union for the use of psilocybin for the treatment of FXS. Following drug approval, NOVA has manufactured a large supply of >98% pure psilocybin for clinical studies and commercialization.
該公司在美國和歐盟都獲得了使用裸蓋菇素治療FXS的孤兒藥物指定。在藥物批准後，Nova生產了大量的>98%的裸蓋菇素用於臨牀研究和商業化。
Recent preclinical research showed that a very low microdose formulation of NOVA's psilocybin compound NM-1001 significantly modulated behavioral and cognitive defects in a genetic model of FXS.
最近的臨牀前研究表明，Nova公司的裸蓋菇素化合物的極低劑量配方NM-1001在FXS的遺傳模型中，顯著調節了行為和認知缺陷。
Photo by Robina Weermeijer on Unsplash
Robina Weermeijer在Unspash上的照片
